EP0728482A2 — Use of hcp specific compounds to enhance erythropoiesis
Assigned to SmithKline Beecham Corp · Expires 1996-08-28 · 30y expired
What this patent protects
Invented is a method of enhancing erythropoiesis in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to the human hcp SH2 domain with a binding affinity greater than fifty-fold higher than the binding affinity wit…
USPTO Abstract
Invented is a method of enhancing erythropoiesis in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to the human hcp SH2 domain with a binding affinity greater than fifty-fold higher than the binding affinity with which the compound binds to a human SH-PTP2 SH2 domain, and, binds to a human src SH2 domain, a human lck SH2 domain, a human fyn SH2 domain and a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such hcp SH2 domain.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.